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ABSTRACT
Objectives: The aim was to explore the views of
professional stakeholders and healthcare professionals
(HCPs) on the linkage of UK National Health Service
(NHS) data for paediatric pharmacovigilance purposes
and to make recommendations for such a system.
Methods: A mixed methods approach including a
literature review, interviews, focus groups and a three-
round Delphi survey with HCPs in Scotland was
followed by a triangulation process using a systematic
protocol. The survey was structured using the
Theoretical Domains Framework of behaviour change.
Items retained after applying the matrix-based
triangulation process were thematically coded. Ethical
approval was granted by the North of Scotland
Research Ethics Service.
Results: Results from 18 papers, 23 interviewees, 23
participants of focus groups and 61 completed
questionnaires in the Delphi survey contributed to the
triangulation process. A total of 25 key findings from
all four studies were identified during triangulation.
There was good convergence; 21 key findings were
agreed and remained to inform recommendations. The
items were coded as practical/technical (eg, decision
about the unique patient identifier to use), mandatory
(eg, governed by statute), essential (consistently
mentioned in all studies and therefore needed to
ensure professional support) or preferable.
Conclusions: The development of a paediatric linked
database has support from professional stakeholders
and HCPs in Scotland. The triangulation identified three
sets of core requirements for a new system of data
linkage. An additional fourth set of ‘preferable’
requirements might increase engagement of HCPs and
their support for the new system.
BACKGROUND AND SIGNIFICANCE
Adverse drug reactions (ADRs) are defined
by the WHO1 as noxious and unintended
responses to a drug which occur at doses
normally used in man. ADRs are more likely
to occur when medicines are used off label.2
Off-label use of medication refers to all
uses of a marketed drug not detailed in
the Summary of Product Characteristics (the
legally binding product information in the
UK for medication) including therapeutic
indication, use in age-subsets, appropriate
strength (dosage), pharmaceutical form and
route of administration. This is of particular
concern in children, who receive proportion-
ately more off-label and unlicensed medi-
cines2–4 than other patient groups. Reported
figures differ, but it is estimated that five out
of eight severe ADRs in paediatric inpatients
are related to off-label use of drugs in
children.5
Reports of ADRs are collected nationally in
many countries, for example, Yellow Card
Scheme in the UK or the Food and Drug
Administration (FDA) Adverse Event
Reporting System (FAERS) Database in the
USA. However, it is widely acknowledged that
these systems underestimate the true preva-
lence of ADRs.6 7 A systematic review of
papers published between 1986 and 2006 on
the views of healthcare professionals (HCPs)
towards ADR reporting found that non-
reporting was related to ignorance and lack
of knowledge of the reporting system (95%),
lack of time or similar reasons (77%), fear of
filing an inappropriate report (72%), indif-
ference and uncertainty about causality
(67%) and the perception that licensed
Strengths and limitations of this study
▪ The mixed methods approach of this study used
several methods to employ the strengths while
addressing the inherent weaknesses of each
method.
▪ No validated instruments were used; the inter-
view and focus group schedules were based on
the initial literature review.
▪ The use of a theoretical approach in the form of
the Theoretical Domains Framework added
robustness to the results of the Delphi, allowed
for a systematic exploration of potential
problems.
▪ The use of a triangulation protocol allowed for a
systematic comparison of findings between the
different methods used.
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drugs are safe (47%7). New approaches of signal gener-
ation to enhance existing systems are required.
There is increasing electronic collection and storage
of healthcare data during routine clinical practice for
the purposes of more efficient clinical communication
and health service administration. However, this con-
temporary and comprehensive information resource
could also facilitate new methodological approaches in
population health research, especially pharmacovigi-
lance. Small-scale studies have already shown that iden-
tification of suspected ADRs is possible using this
routine data.8 It is unclear, however, how stakeholders
such as national (Scottish) experts on pharmacovigi-
lance, confidentiality or data protection and HCPs
would view the secondary use of routinely collected
healthcare data, especially if individual datasets were
linked. The research reported here was part of the
CHIMES (Child Medical Records for Safer Medicines)
programme in Scotland. The overall aim of this pro-
gramme was to develop a novel paediatric pharmacov-
igilance system based on linkage of routinely collected
data in primary (general practice (GP) and community
pharmacy) and secondary (hospital) care. The aim of
this research was to provide recommendations for such
a national resource that would allow monitoring for
long-term outcomes of exposure to medicines during
childhood and adolescence. Adverse reactions to medi-
cines could be identified by stop dates, reduction of
initial doses or switches of medication. In line with use
of other existing datasets derived from routinely col-
lected data, our assumption was that access to the data
by researchers would only be allowed after review of
the application by an internal ethics, or equivalent,
committee.
OBJECTIVE
The aim of this study was to explore the views and opi-
nions of HCPs on linking routinely collected data and
make evidence-based recommendations for a system of
pharmacovigilance based on linked data.
METHODS AND MATERIALS
This was a mixed methods study which included data
from a literature review,9 an interview study,10 a focus
group study11 and a Delphi survey.12 All these studies
have been previously reported. In this paper, the results
of the four stages of data collection are formally triangu-
lated, and recommendations for a new system of phar-
macovigilance are made. All studies were approved by
the North of Scotland Research Ethics Service and
National Health Service (NHS) Research and
Development.
Summaries of the methods used in the previously
reported papers are presented below.
The systematic literature review of published papers
described the views of HCPs to data sharing and linkage.
Searches were performed in Medline, EMBASE,
SCOPUS, CINAHL and PsychINFO for papers in
English between 2001 and 2011.9
The interviews explored the views of a purposive
sample of Scottish stakeholders on pharmacovigilance,
confidentiality/patient privacy, data protection, accept-
able and non-acceptable usage of data and dissemin-
ation of findings. Interviews were semistructured, were
audio-recorded and fully transcribed. A framework
approach was used to identify themes inductively, but
the analysis approach also allowed for the identification
of emergent themes.10
Focus groups were conducted with pharmacists,
nurses, general practitioners and paediatricians, from
primary and secondary care. Stratified purposive sam-
pling was used to ensure inclusion of participants from a
range of urban, rural and remote settings and geo-
graphic locations across Scotland. Paediatric experience
was preferred but not essential. Invitation packs were
mailed to potential participants. Building on the inter-
views, the focus groups explored views of the proposed
linkage and identified perceived barriers. All focus
groups were audio-recorded and transcribed verbatim.
Themes were identified via a framework approach.11
Based on the findings of the two qualitative studies, a
three-round Delphi survey with HCPs (pharmacists,
nurses and medical doctors with an interest in paediat-
ric medicine) in Scotland was conducted to identify
consensus on essential system components required for
HCPs to support or facilitate the proposed data linkage
and continue recording the necessary data.12
A random sample was drawn from national sampling
frames of the target populations, using, for example,
the NHS Information Service Division workforce lists
for general practitioners and practice nurses, a list of
registered premises by the Practitioner Service Division
for community pharmacists or paediatricians via the
Scottish Paediatric Society. The survey was structured
using the Theoretical Domains Framework (TDF)13 of
behaviour change. A systematic data reduction exercise
based on methods proposed by Prior et al14 was
applied between Round 1 and 2. Consensus criteria for
each round were set a priori at 66.7% for Round 2 and
90% for Round 3.
A triangulation protocol based on the methods pro-
posed by Farmer et al15 was applied to interpret and inte-
grate key findings from the literature review and the
three empirical studies in order to identify essential
system components. These methods proceeded in three
steps. First, a matrix was constructed to allow compari-
son of key issues against those as represented in the indi-
vidual studies. Second, themes were compared to create
a single list of issues, barriers and facilitators based on
the individual study results. Third, agreement between
studies was coded using a convergence coding scheme
as presented in table 1. ‘Agreement’ indicates that the
key finding was identified in a particular study, ‘partial
agreement’ means that the finding was partially covered,
and ‘disagreement’ indicates a contradictory finding.
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If none of these three codes could be attributed, the
label ‘silence’ was used.
RESULTS
In the literature review, which was conducted in 2011, a
total of 2917 titles were screened and 18 papers were
included, describing the views of HCPs on linking or
sharing healthcare data at an individual patient level.9
These showed that data sharing at a patient identifiable
level was more common than population-based data
linkage. Data sharing was often described within specific
settings, such as an emergency department or a special-
ist ward or the pharmacy department of a hospital.
HCPs who reported a previous positive experience with
such data sharing perceived a positive impact on their
work and patient safety and were more likely to support
data sharing. However, funding (start-up and mainten-
ance), technical problems (compatible Information
Technology (IT) systems) and governance issues were
identified as potential barriers to successful implementa-
tion of data sharing.
Between February and October 2010, 25 participants
were interviewed from 11 of the 24 Scottish Health
Boards.10 Interviewees had positive views on the pro-
posal to use routinely collected data to create a pharma-
covigilance resource for children in Scotland. Practical,
ethical and legal issues were identified related to the
sharing of the data, the ownership of the linked data,
consent for data linkage, anonymisation and confidenti-
ality. These results were further explored in focus groups
with health practitioners.
Between August 2010 and May 2011, six focus groups
were conducted with 22 participants from seven differ-
ent Scottish Health Boards.11 Participants were
recruited from all professional backgrounds and from
primary and secondary care. Half of the participants
were pharmacists (n=11, 50%) and the majority were
female (n=13, 59%). Focus group participants reported
that governance problems and relevant legislation
should be addressed. They proposed that patients
would have issues with the use of their data for research
purposes, with key areas of sensitivity including confi-
dentiality and third party access to patient identifiable
data. Participants supported the proposed linkage, and
their range of views was similar to those of the national
interviewees. However, more concerns were voiced
about funding of such data linkage, particularly if this
meant any diversion of funds from their own area of
practice.
The Delphi study was conducted in three rounds from
August 2011 to February 2012.12 The first round of the
Delphi study generated over 1000 individual statements
from 61 participants. After systematic item reduction,
149 items were retained for the second round, in which
participants were asked to rate their level of agreement
with each item. Items reaching the consensus criterion
of 66.7% were entered into the third round. After the
third round, the retained consensus items focused on
professional standards, requirements for linkage and the
use and form of potential feedback. Overall, the results
confirmed that participants were generally willing to
facilitate the proposed linkage, dependent on adher-
ence to professional standards, relevant legislation,
ethical approval, secure data sharing agreements and
support from their employers.
Applying the triangulation protocol, a total of 25 key
findings were identified across all four studies and the
interstudy level of agreement is shown in table 2.
Findings showed near perfect agreement (full or
partial) between the qualitative studies (23/25, 92%).
No disagreement on any finding was noted between the
qualitative studies, but each of the qualitative studies had
one coding of ‘silence’: Focus group participants did not
discuss whether data ownership would have to be clari-
fied, and interview participants did not identify feedback
from linkage studies as a facilitator of future support.
Four of the 25 findings (16%) from the qualitative
studies were not carried forward in the Delphi survey,
that is, the predefined consensus criteria were not
reached; of the remainder, three results (3/25, 12%)
from the survey findings did not reflect the findings
from the qualitative arm, namely, the role of the UK
NHS as a facilitator of the data linkage, whether benefits
outweighed the risks or if professional guidelines would
prevent data sharing.
All but four of the findings identified in the empirical
studies were also identified in the systematic review.9
Understanding of pharmacovigilance and understanding
of the current system were not identified in the litera-
ture review, nor were the two Scotland-specific findings
(NHS as a facilitator or the use of the Community
Health Index (CHI) as a unique patient identifier).
Essential system components were deduced from the
Delphi analysis plus key findings that showed (partial)
agreement across at least three studies as listed in
table 1. Statutory items, such as legislation, were
included as following the law would be the basis of any
decision. Key findings were sorted into inductively and
resulted in four categories: practical/technical, manda-
tory, essential or preferable. Practical requirements
include the need for meaningful data, the provision of
server space for storage and processing the linked data
as well as software compatibility across and within the
different Health Boards in Scotland. General agreement
was that any technical or practical problems could be
Table 1 Convergence coding scheme for triangulation
protocol (based on Farmer et al15)
Coding label Convergence coding
Agreement Finding has been identified
Partial agreement Finding is covered partially
Disagreement Finding is contradicted
Silence Finding does not appear
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solved. Mandatory items were those underpinned by
regulation or statute/legislation. Literature and partici-
pants identified that following ‘relevant’ legislation is
important but a definition of relevant was seldom pro-
vided or discussed. Focus group participants declined
requests to be more specific and referred to legal specia-
lists instead. Indeed, the interview partners with legal
expertise identified the widest range of legislative acts
and non-statutory guidelines that should be observed.
Additionally, participants deemed ethical approval to be
important. Essential items were those in which there was
(at least partial) consensus across at least three of the
four studies (as listed in table 2), for example, that the
planned data linkage should not impact negatively on
the current workload or clear information governance
structures. Participants stipulated that transparency
should include informing the public about the new
system. Items coded as ‘preferable’ were those that did
not match the above definitions but were deemed to
increase the stakeholders’ support and active engage-
ment with the system. Clear data sharing agreements in
place as well as feedback from the linked data resources
Table 2 Overview of identified key issues and how they triangulate across the literature review and the three studies
Key finding
Literature
review Interviews
Focus
groups Delphi survey
Limited knowledge of available databases. Agreement Agreement Agreement Agreement
Understanding of pharmacovigilance based on WHO
definition.
Not addressed Partial
agreement
Partial
agreement
Not addressed
Limitations of current pharmacovigilance systems. Not addressed Agreement Agreement Not addressed
Data linkage is useful for pharmacovigilance research. Agreement Agreement Partial
agreement
Partial
agreement
Adherence to legislation is necessary. Agreement Agreement Agreement Not addressed
It is not clear which legislation is relevant. Partial
agreement
Agreement Agreement Not addressed
Data quality is important for data linkage. Agreement Agreement Agreement Partial
agreement
The responsibility for the linked data lies with the data owner. Silence Agreement Partial
agreement
Silence
Data ownership needs to be clarified. Partial
agreement
Agreement Silence Agreement
The NHS should be a facilitator of the data linkage. Silence Partial
agreement
Agreement Disagreement
The benefits of the data linkage outweigh the risks. Partial
agreement
Agreement Partial
agreement
Disagreement*
Professional guidelines might prevent data sharing. Silence Agreement Partial
agreement
Disagreement
Conditional support if data linkage available. Agreement Agreement Agreement Agreement
Information governance is a facilitator of data linkage. Agreement Agreement Agreement Agreement
Feedback from studies using the linked data is a facilitator. Agreement Silence Agreement Agreement
Anonymisation is mandatory. Partial
agreement
Partial
agreement
Agreement Agreement
Information of and input from the public is important. Agreement Agreement Agreement Agreement
An opt-out option for patients is acceptable. Agreement Partial
agreement
Partial
agreement
Agreement
Technical problems can be solved. Agreement Agreement Agreement Agreement
Use of CHI number is acceptable. Silence Agreement Agreement Agreement
Safeguards like sanctions should be used. Agreement Agreement Partial
agreement
Silence
Ethical approval will be required. Agreement Agreement Agreement Agreement
Data linkage should not impact negatively on current workload. Agreement Agreement Agreement Agreement
A certain amount of patient identifiable data will be necessary
for the linkage.
Agreement Agreement Agreement Silence
Assurance of confidentiality would facilitate support. Agreement Partial
agreement
Partial
agreement
Agreement
Bold font indicates agreement across three or more arms.
Agreement: key finding has been identified; partial agreement: finding is partially covered; disagreement: contradictory statement; silence: not
apparent; not addressed: subject not addressed in study.
*Disagreement only in the way that this was mentioned but dropped across the rounds, indicating that there was no consensus on this item,
hence disagreement rather than silence.
CHI, Community Health Index.
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and an opt-out possibility for patients was deemed
acceptable, but HCPs requested to evaluate patients’ opi-
nions prior to the implementation of the new system.
Figure 1 indicates how the findings resulting from the
triangulation process are mapped out displaying the
conceptual model for the new system implementation.
DISCUSSION
Main findings
The triangulation process identified three core sets of
requirements necessary for the implementation of a new
linked data system for paediatric pharmacovigilance,
including ‘practical/technical’ requirements as well as
‘mandatory’ requirements such as ethical approval, and
‘essential’ requirements such as transparency. A fourth
set of requirements, labelled ‘preferable’, might increase
the engagement of HCPs with such a new system.
Strengths and limitations
Triangulation has been described since the 1970s16 and
was initially defined as ‘the combination of methodolo-
gies in the study of the same phenomenon’ (Denzin,
1978, p. 291, as seen in16 17). The combination can be
across different data sources, investigators, theories,
methodologies or data collection methods.16 17
O’Cathain et al18 defined triangulation as investigating
the same issue using different methods—an approach
well suited to mixed methods research. The use of a tri-
angulation protocol allowed for a systematic comparison
of findings between the different methods used. The use
of a mixed methods approach allowed minority issues in
the interviews to be carried forward, that is, issues that
were only mentioned by one or two participants. The
Delphi survey results that were based on those findings
confirmed overlapping findings between the different
studies, providing face validity and robustness of the find-
ings against method-based variation. The initial Delphi
questionnaire was developed based on the findings from
the interview and focus group study in order to present
those findings to a larger audience with the aim of
gaining consensus on the most important items.
Although the questionnaire was not psychometrically
validated, it incorporated the use of a tested and vali-
dated framework allowing for a systematic assessment of
barriers to data linkage, the TDF.13 The TDF accounted
for all barriers identified in the qualitative studies, hence
confirming good empirical coverage. Using several
methods gave the capacity to employ the strengths and
address the inherent weaknesses of each method.
The single studies involved in the triangulation took
place over a period of 2 years. Some of the opinions
from the stakeholders and HCPs might have changed
over that time. We did not retest their views and opi-
nions a second time. We are, however, confident that
this triangulation work does indeed present a good start-
ing point of the requirements for such a suggested data
linkage project. Once the proposed system has been
implemented, surveys among data providers and data
users should be performed on a regular basis to ensure
that the way the data linkage is performed and analysed
is still acceptable for HCPs.
This paper has not considered the opinions of
patients/the public towards the secondary use of rou-
tinely collected data; these have been explored in a par-
allel study which is currently being analysed.
Views towards routinely linked NHS data
The proposed data linkage was perceived to be useful
for pharmacovigilance research across all methods used
in this study. Small-scale studies have already indicated
that it is possible to use linked data for epidemiology
research19–22 and that linked data can be used success-
fully for signal generation relevant to possible ADRs.8
Participants indicated conditional support for the pro-
posed linkage, with conditions ranging from anonymisa-
tion of the data to ethical approval as well as adherence
to legislation and professional codes of conduct. A
range of potentially relevant legal frameworks was identi-
fied during the interviews including the Data Protection
Act 1998, the Common Law Duty of Confidentiality, and
the Human Rights Act 1998.10 In the qualitative studies,
there was confusion as to which legislation, which guide-
lines and standards were directly relevant to the pro-
posed data linkage.10 Several statements included
potential regulatory and legislative frameworks but did
not discuss any of these in detail as it was assumed that
‘relevant’ laws and guidelines would be followed.
Despite probing, participants in focus groups did not
provide further information on the term ‘relevant’,
referring to experts that would be better suited to
answer these questions despite the fact that even those
experts interviewed commented that these had rarely
been formally tested in a court of law.
Figure 1 Building blocks of recommendations for the
proposed data linkage system. Practical requirements
describe practical and technical necessities for the actual data
linkage process, mandatory requirements describe
compliance with relevant legislation, essential requirements
describe system design options and preferable items describe
items that would increase the support from HCPs. ADR,
adverse drug reaction; CHI, Community Health Index; HCPs,
healthcare professionals; IT, Information Technology.
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The definition of ‘relevant’ is important for the appli-
cation of legislation and guidelines, and for the anon-
ymisation of data. Participants also used the term
‘adequate’ in the context of anonymisation of data
security measures. However, neither the reviewed litera-
ture nor the empirical work provided a working defin-
ition of these terms or criteria for ‘adequacy’. It would
be necessary to have an agreed definition in order to
apply ‘relevant’ and ‘adequate’ measures, and also it
would be important to specify who should decide what
‘relevant’ and ‘adequate’ means.
The findings suggest that the benefits of the proposed
data linkage would outweigh the risks to patient privacy
and confidentiality although the concerns about pos-
sible risks might have caused participants in all three
methods to conclude that ‘ethical approval is required’.
However, participants did not specify what kind of
ethical approval would be expected. The options would
be approval by the National Research Ethics Service
(NRES) and/or an internal ethics committee specific
for the linked data. Some of the data providers in
Scotland, such as the Health Information Centre (HIC)
in Tayside or the NHS Information Service Division
(ISD), already have internal ethics approval boards that
assess requests for data access.23 The internal approval
board for ISD, the Privacy Advisory Committee (PAC),
additionally demands that any requests to access patient
identifiable data or data linkage projects are reviewed by
an NHS ethics committee prior to submission to PAC.24
In conjunction with the expressed views of HCPs that
the NHS should be a facilitator of the data linkage, this
could mean that the standards employed by NHS ISD as
the biggest data collector of the Scottish NHS would
find widespread HCP approval. However, this and the
other two suggestions of an independent user like PAC
or the government, for example, the Department of
Health, was not endorsed in the Delphi survey. No con-
sensus emerged indicating a high level of uncertainty
among the HCP community about the governance of
linked health data. The findings from this work indicate
an awareness that a certain amount of patient identifi-
able data would be necessary in order for the proposed
data linkage system to function. This finding is not new,
as a Wellcome Trust report25 has highlighted that the
use of clinical data is rarely fully anonymous. Current
standards employed by the NHS do recognise this, as
approval is required from NHS ethics committees, and
requests for patient identifiable data will have to be
approved by relevant Caldicott guardians to ensure that
only the minimum amount of identifiable data is used
to answer the questions being posed.26 A Caldicott
guardian is the person responsible within NHS struc-
tures in the UK to ensure adherence to a set of princi-
ples and processes which provide a framework of quality
standards for the management of confidentiality and
access to patient information.26 The General Medical
Council (UK) would prefer anonymised disclosures of
data although it acknowledges that the release of patient
identifiable information might be justified in the public
interest.27
Requirements for data linkage
Based on these findings, the following requirements
might be appropriate to consider before implementing
a system of pharmacovigilance based on linked health-
care data:
1. Practical/technical: storage space for data, software
compatibility;
2. Mandatory: to comply with law and professional
guidance;
3. Essential: to ensure support of HCPs;
4. Preferable: to increase support and active engage-
ment with the system.
‘Practical’ requirements include the need for mean-
ingful data, in order to have data that are useful and the
provision of server space for storage and processing the
linked data. A Wellcome Trust report published in 2009
suggested the use of ‘safe havens’ for data linkage pro-
jects.25 Software compatibility across and within the dif-
ferent Health Boards in Scotland was also questioned by
participants. The lack of a single standard system for
reporting and recording medical data has been noted
previously.28 Despite this, results indicated that any tech-
nical or practical problems could be resolved.
Compliance with relevant legislation was seen as ‘man-
datory’. The following acts were identified as relevant
for the planned project: the Data Protection Act 1998
and the Common Law Duty of Confidentiality. In add-
ition to the law, compliance with professional standards
and ethical approval were deemed to be important. For
all recommendations, clear definitions are required.
This would be in addition to the terms ‘relevant’ and
‘adequate’ as discussed above.
‘Essential’ requirements describe system options that
would ensure the support of HCPs for the planned data
linkage. One of these requirements would be that the
planned data linkage should not impact negatively on
the current workload, which is in line with previous find-
ings.29–33 Clear information governance structures were
requested across all arms of this study. Concerns about
governance including data security, legal restrictions and
data quality are not new and have been cited previously
as potential barriers to data sharing.31 34–40 Potential
governance structures could relate to consent and confi-
dentiality structures as well as the use of data sharing
agreements. Similar features have been recently
described by El Emam et al40 as facilitators for data
sharing. Participants also requested transparency about
the kind of data used and the research initiated and
informing the public about the proposed system.
‘Preferable’ items would increase the support from
HCPs, hopefully leading to a more active engagement in
the new system design. Feedback from the linked data
resources was seen as a strong motivator for HCPs.
Frontline HCPs saw feedback as an opportunity to
review their own practice. Feedback was requested in an
6 Hopf YM, et al. BMJ Open 2016;6:e011879. doi:10.1136/bmjopen-2016-011879
Open Access
‘easy-to-digest’ format with the possibility of accessing
further information if required. In particular, interview
participants saw feedback as a chance to enable data
providers to increase data quality and with this the
quality of the linked data. In this context, Aylin et al20
found that the quality of the data sent to the Hospital
Episodes Statistics in England improved over time as a
consequence of regular feedback to participating hospi-
tals. The qualitative studies identified the belief that if
the feedback provided ultimately benefitted patients,
HCPs would become more interested in ensuring high
quality data entry. In terms of consent, participants saw a
discussion about consent as necessary, although they
concluded that requesting explicit consent from all
patients in Scotland would be unfeasible. This is in con-
trast to Patel’s findings,33 where only a minority of parti-
cipants thought the request of individual consent would
be too complicated and time-consuming. An opt-out
possibility was deemed acceptable for patients, although
HCPs requested that this assumption should be con-
firmed with the general public prior to the implementa-
tion of the new system. Finally, in particular frontline
HCPs would prefer to have clear data sharing agree-
ments in place which is in line with previous findings of
El Emam et al.40
Taking all four categories into account, the first three
would describe the basis for the proposed new system,
with the fourth increasing support from HCPs (as
detailed in figure 1).
CONCLUSION
The proposed data linkage was perceived as addressing a
gap in current knowledge. Nonetheless, participants did
identify a range of problems and concerns that should
be addressed prior to implementation of such a system.
Adherence to relevant legislation, such as the Data
Protection Act, and the application of appropriate gov-
ernance, such as adherence to professional standards
and the Caldicott principles, were deemed to be import-
ant in ensuring confidentiality for patients and prescri-
bers. Although no consensus was reached in the first two
studies on the need for consent, the Delphi study identi-
fied that the offer of an ‘opt-out option’ for patients
would have support from HCPs.
The work presented in this paper demonstrates that
the development of a paediatric linked database for
pharmacovigilance has support from professional stake-
holders and HCPs in Scotland together with specific
recommendations to inform the design of such a system.
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